Clinical trials: Nasopharyngeal Neoplasms
Nasopharyngeal Carcinoma
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
This study is aimed to investigate the short-term efficacy and toxicities of local advanced nasopharyngeal carcinoma (NPC) treated with TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy and…
- Trial name
- NCT03557112
- Testing
- Nimotuzumab, Cisplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Guiyang Medical University
Head and Neck Cancer
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00891904
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Nasopharyngeal Carcinoma
GNT Induction Treatment in Locally Advanced NPC
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal…
- Trial name
- NCT06026878
- Testing
- gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Air Force Military Medical University, China
Lymphoma, Nasopharyngeal Cancer
Applying PET/MR in Oncology - a Prospective Project
Cancer is a global health issue. According to the World Health Organization, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.
- Conditions
- Lymphoma, Nasopharyngeal Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT04158414
- Testing
- PET/MR scan
- Volunteers
- 500 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Nasopharyngeal Carcinoma
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal…
- Trial name
- NCT05524168
- Testing
- SBRT, Camrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with metastatic or…
- Trial name
- NCT00003443
- Testing
- bryostatin 1
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Target Volume Delineation, Early-stage Nasopharyngeal Carcinoma
Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients
To analyze the long-term results and toxicities of the reducing clinical target volume (CTV) delineation method in early-stage nasopharyngeal carcinoma (NPC) patients treated with intensity modulated radiation therapy (IMRT).
- Conditions
- Target Volume Delineation, Early-stage Nasopharyngeal Carcinoma, Intensity Modulated Radiation Therapy
- Trial name
- NCT03839602
- Testing
- Reducing CTV
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Nasopharyngeal Carcinoma
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Trial name
- NCT06323239
- Testing
- SBRT, Low-dose Radiotherapy (LDRT), Toripalimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nasopharyngeal Carcinoma
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
This study is to investigate the efficacy and safety of the induction chemotherapy + concurrent chemoradiotherapy（CCRT）combined with toripalimab and endostar treatment, in comparison with the induction chemotherapy + concurrent…
- Trial name
- NCT04447326
- Testing
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, IC＋CCRT
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
Because nasopharyngeal carcinoma （NPC）is very sensitive to radiation and the specificity of the anatomical structure, radiotherapy has become the core treatment for NPC.
- Trial name
- NCT06156878
- Testing
- Anti-EGFR and PD-1 inhibitor arm
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors.
- Trial name
- NCT00212108
- Testing
- celecoxib, gefitinib
- Where
- Singapore
- Volunteers
- 22 people
- Sponsor
- National University Hospital, Singapore
Nasopharynx Cancer
Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx
The purpose of this study is to collect outcomes information to see what effects photon/proton beam radiation has on nasopharynx cancer.
- Trial name
- NP01 (NCT00797290)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
Nasopharyngeal Carcinoma
Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (docetaxel+cisplatin+fluorouracil) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal…
- Trial name
- NCT01245959
- Testing
- Docetaxel, cisplatin and fluorouracil, Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC)…
- Trial name
- NCT01417390
- Testing
- Drug: Gemcitabine and cisplatin, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First People's Hospital of Foshan
HIV Infection, Recurrent Anal Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
This phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and human…
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer
- Trial name
- NCT01249443
- Testing
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium